Company Profile
Benitec Biopharma Stock Price, News & Catalysts
- Ticker:
- BNTC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Australia and listed in the U
Stock performance
8.64 USD (-6.90%)
Close
Last updated: November 5, 2026
363M USD
Market cap
Why the stock is moving
As of Nov 5, 2026, BNTC closed down 6.90% at $8.64. No new same-company headline was identified in the current news window.
Company overview
Genetic Medicine Company
Benitec Biopharma develops genetic medicines for neuromuscular and other inherited disorders. Its approach combines gene silencing with gene replacement in a single therapeutic construct.
Silence and Replace Platform
The company's DNA-directed RNA interference technology is designed to suppress expression of a disease-causing gene while introducing a functional replacement copy. This dual mechanism is intended to address dominant genetic diseases in which simply adding a healthy gene may be insufficient.
BB-301 Lead Program
BB-301 is an AAV9-based gene therapy for oculopharyngeal muscular dystrophy, or OPMD. It is administered to pharyngeal muscles and is designed to reduce mutant PABPN1 transcripts while expressing a codon-optimized functional PABPN1 protein.
Focus on Dysphagia in OPMD
OPMD progressively weakens the muscles involved in swallowing and can lead to aspiration, malnutrition, and loss of independence. BB-301 development focuses on improving swallowing function by treating the underlying muscle pathology.
Clinical Development Strategy
The Phase 1b/2a program evaluates safety, biological activity, and functional swallowing outcomes across dose cohorts. Benitec is using clinical data together with its natural-history study to select endpoints and prepare a pivotal development program.
Future catalysts
- Initiation of a pivotal study of BB-301 in OPMD in mid-2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Benitec Biopharma (BNTC)?
Benitec Biopharma (BNTC) most recently closed at 8.64 USD, a -6.90% move versus the previous session.
What is the market cap of Benitec Biopharma (BNTC)?
Benitec Biopharma currently has a market capitalization of 363M USD on BioPharmSignal.
What does Benitec Biopharma do?
Genetic Medicine Company Benitec Biopharma develops genetic medicines for neuromuscular and other inherited disorders. Its approach combines gene silencing with gene replacement in a single therapeutic construct. Silence and Replace Platform The company's DNA-directed RNA interference technology is designed to suppress expression of a disease-causing gene...
On which exchange is BNTC stock listed?
Benitec Biopharma (BNTC) is associated with NASDAQ, Australia and listed in the U, Biopharma.
What is BB-301?
Initiation of a pivotal study of BB-301 in OPMD in mid-2027.
Which conditions is Benitec Biopharma targeting with BB-301?
Benitec Biopharma is associated with genetic disease based on its company overview and current catalyst commentary.
How does Benitec Biopharma describe recent progress with BB-301?
Initiation of a pivotal study of BB-301 in OPMD in mid-2027.
What is Genetic?
Genetic Medicine Company Benitec Biopharma develops genetic medicines for neuromuscular and other inherited disorders.